Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging  by Taillefer, Raymond et al.
Acute Beta-Blockade Reduces the Extent
and Severity of Myocardial Perfusion Defects With
Dipyridamole Tc-99m Sestamibi SPECT Imaging
Raymond Taillefer, MD, FRCP,* Alan W. Ahlberg, MA,† Yasmin Masood, MD,†
C. Michael White, PHARMD,‡ Isabella Lamargese, MD, FRCP,* Jeffrey F. Mather, MS,‡
Carol C. McGill, LPN,† Gary V. Heller, MD, PHD, FACC†
Montre´al, Canada; and Hartford and Farmington, Connecticut
OBJECTIVES The goal of this study was to examine the effect of acute beta-blockade on dipyridamole
Tc-99m sestamibi myocardial perfusion imaging (DMPI).
BACKGROUND Studies suggest that antianginal drugs may reduce the presence and severity of myocardial
perfusion defects with dipyridamole stress. However, there are no data regarding specific
drugs.
METHODS Patients with catheterization-proven coronary artery disease (CAD) were enrolled in this
prospective, double-blind, placebo-controlled study and randomly assigned to DMPI after
placebo, low-dose metoprolol (up to 10 mg), and high-dose metoprolol (up to 20 mg).
Patients underwent one Tc-99m sestamibi study at rest on a separate day. The interval
between DMPI studies was 14 days. Images were interpreted by three observers blinded to
clinical data using a 17-segment, five-point model. For each image, a summed stress score
(SSS), summed rest score (SRS), and summed difference score (SDS) were calculated (SDS
 SSS  SRS). Images with an SSS 4 were considered normal.
RESULTS Twenty-one patients completed all four Tc-99m sestamibi studies. The sensitivity of DMPI
for detection of CAD was 85.7% with placebo versus 71.4% with low- and high-dose
metoprolol. In comparison with placebo, the SSS was significantly lower (p 0.05) with low-
and high-dose metoprolol (12.0 10.1 vs. 8.7  9.0 and 9.3  10.6, respectively). The SDS
also was significantly lower (8.4  8.8 with placebo vs. 5.0  6.7 [p  0.001] and 5.4  7.9
[p  0.01] with low- and high-dose metoprolol, respectively).
CONCLUSIONS The presence and severity of CAD may be underestimated in patients receiving beta-blocker
therapy undergoing dipyridamole stress myocardial perfusion imaging. (J Am Coll Cardiol
2003;42:1475–83) © 2003 by the American College of Cardiology Foundation
The value of stress myocardial perfusion imaging (MPI) in
the assessment of patients with known or suspected coro-
nary artery disease (CAD) is well documented. Although
the diagnostic accuracy of exercise and pharmacologic MPI
is high and similar, various factors may negatively impact
sensitivity. The inability to achieve 85% of maximal pre-
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dicted heart rate with exercise can lead to an underestima-
tion of the presence and extent of CAD as detected by MPI
(1–3). Concomitant antianginal drug therapy also has been
shown to affect MPI results with exercise (4–8) and
dobutamine (9). Due to competitive inhibition, caffeine-
containing products negatively affect vasodilator MPI
(10,11).
Patients receiving antianginal drugs may be referred for
vasodilator stress under the assumption that these medica-
tions have no impact on MPI results (12–14). However,
Sharir et al. (15) evaluated patients with dipyridamole MPI
and found a significant reduction in the presence, extent,
and severity of defects when patients did not discontinue
antianginal medications before testing. One class of cardiac
drugs, beta-blockers, are commonly used in the treatment of
angina. Although beta-blockers have been shown to reduce
detection of CAD with MPI using exercise or dobutamine
(4–9), there are no data regarding beta-blockers with
vasodilator MPI. The purpose of this study was to examine
the effects of acute beta-blocker therapy upon vasodilator
MPI in patients with CAD.
METHODS
Study design. This was a prospective double-blind,
placebo-controlled, randomized study in which patients
with CAD were submitted on separate days to dipyridamole
Tc-99m sestamibi single-photon emission computed to-
mography (SPECT) imaging without supplemental exercise
(dipyridamole myocardial perfusion imaging [DMPI]) after
randomized acute administration of placebo, low-dose
metoprolol, and high-dose metoprolol. Myocardial perfu-
sion studies were performed at two centers: the Department
of Nuclear Medicine of the Centre Hospitalier de
l’Universite´ de Montre´al and the Nuclear Cardiology Lab-
oratory, Hartford Hospital, Hartford, Connecticut.
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Patient population. Twenty-five patients with stable
CAD were prospectively evaluated. Inclusion criteria were
evidence of obstructive CAD, defined as a 70% stenosis in
at least one major coronary artery, on coronary angiography,
without subsequent revascularization, within 12 weeks of
enrollment. All patients provided written informed consent
as approved by both institutional review boards.
Exclusion criteria were left main disease, hypertrophic
cardiomyopathy or aortic stenosis, myocardial infarction
30 days, unstable angina 7 days, uncontrolled systemic
hypertension (systolic blood pressure 200 mm Hg or
diastolic blood pressure 110 mm Hg), severe valvular
disease, percutaneous coronary intervention 3 months,
coronary artery bypass graft surgery 6 months, history of
malignant ventricular arrhythmia, history of reversible air-
ways disease, or history of allergy to dipyridamole or
aminophylline.
Study protocol. Beta-blockers and calcium antagonists
were withheld 48 h and 24 h, respectively, before each
appointment after approval by the patient’s primary physi-
cian. Patients were advised to refrain from consumption of
products containing caffeine for24 h before each appoint-
ment. For the first appointment, patients underwent acute
metoprolol titration without DMPI. The purpose of this
preliminary trial was to: 1) determine the dosage of meto-
prolol required for the subsequent low- and high-dose
beta-blocker conditions before DMPI, and 2) permit ran-
domization of the treatment conditions.
For the next three appointments, each patient was sub-
mitted to standard DMPI after three different treatment
conditions, assigned in random fashion: 1) placebo (normal
saline solution), 2) acute administration of low-dose meto-
prolol, and 3) acute administration of high-dose metoprolol.
The time interval between each DMPI study was 7 but
14 days. On a separate day and before the DMPI studies,
patients underwent Tc-99m sestamibi SPECT imaging at
rest.
Metoprolol titration protocol. A total of 4 mg of meto-
prolol was infused over 4 min followed by a 5-min wait
before administration of the next 4-mg dose to a total
cumulative dose of 12 mg. If a titration end point was not
achieved after a total cumulative dose of 12 mg, 2 mg was
infused over 2 min followed by a 5-min wait before
administration of the next 2-mg dose, to a total cumulative
dose of 20 mg. Titration end points were: 1) reduction in
baseline heart rate25%; 2) reduction in baseline heart rate
15% after a total cumulative metoprolol dose of 20 mg.
The metoprolol infusion was terminated if patients achieved
either of the following exclusion end points: 1) reduction of
systolic blood pressure 90 mm Hg, 2) heart rate 45
beats/min, 3) significant side effects including bronchos-
pasm or congestive heart failure, or 4) atrioventricular block
greater than second degree-Mobitz I. Symptoms and three-
lead electrocardiogram (ECG) were continuously moni-
tored, and heart rate and blood pressure were measured and
recorded before the next dose of metoprolol.
Metoprolol and placebo administration before dipyrid-
amole stress. Administration of metoprolol for the low-
and high-dose conditions followed the same titration regi-
men described above. For each patient, the exact dosage of
metoprolol achieved with the preliminary trial was admin-
istered for the high-dose condition. The dosage of meto-
prolol for the low-dose condition was 50% of that achieved
with the preliminary trial. For the placebo condition,
normal saline (4 ml) was infused over 4 min followed by a
5-min wait before administration of the next 4-ml dose for
a total cumulative dose of 12 ml. A total of 10 min after the
last dose of placebo, low-dose metoprolol, or high-dose
metoprolol patients underwent DMPI.
Abbreviations and Acronyms
CAD  coronary artery disease
DMPI  dipyridamole myocardial perfusion imaging
LAD  left anterior descending coronary artery
MPI  myocardial perfusion imaging
RCA  right coronary artery
SDS  summed difference score
SPECT  single-photon emission computed tomography
SRS  summed rest score
SSS  summed stress score
Table 1. Effects of Acute Low-Dose and High-Dose Metoprolol Administration on
Hemodynamic Parameters at Rest
Baseline Post-Administration p Value
Low-dose metoprolol (9.0  1.9 mg)
HR (beats/min) 72  12 61  8 0.001
SBP (mm Hg) 142  15 135  13 0.019
DBP (mm Hg) 73  11 71  9 0.058
Rate-pressure product (HR  SBP) 10,340  2,350 8,350  1,410 0.001
High-dose metoprolol (18.0  3.9 mg)*
HR (beats/min) 72  11 59  7 0.001
SBP (mm Hg) 139  19 131  17 0.001
DBP (mm Hg) 73  11 70  11 0.014
Rate-pressure product (HR  SBP) 9,980  1,920 7,840  1,460 0.001
*There were no significant differences in any of the hemodynamic parameters at baseline or after beta-blocker administration
between the low-dose and high-dose metoprolol treatment conditions.
DBP  diastolic blood pressure; HR  heart rate; SBP  systolic blood pressure.
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Dipyridamole stress. Dipyridamole (0.56 mg/kg) was in-
fused over 4 min. Patients’ symptoms and three-lead ECG
were continuously monitored. A dose of 30 to 45 mCi of
Tc-99m sestamibi was injected 7 to 9 min after initiation of
the infusion. The same dose was used for the rest study.
Tc-99m sestamibi imaging. Electrocardiogram-gated
SPECT acquisition began 60 to 90 min after injection of
radiopharmaceutical for rest, and DMPI and was performed
using a dual-head SPECT camera (SMV/DST at HDM
and ADAC/Vertex at HH) equipped with a 3/8” sodium
iodide crystal and a low-energy, high-resolution collimator.
Sixty-four projections (20 to 25 s/projection) were obtained
over a 180-degree semicircular arc extending from right
anterior oblique to left posterior oblique view. Filtered back
projection was acquired using a Butterworth filter with a
frequency cut-off of 0.66 cycles/pixel and an order of 5 for
reconstruction of the transaxial slices to a thickness of 6.6
mm. No attenuation correction was used.
Image interpretation. All SPECT data was submitted to
the same laboratory (Hotel-Dieu de Montre´al, Montreal,
Canada) for reconstruction and preparation of images for
uniform display. All images were interpreted at the other
laboratory (Hartford Hospital, Connecticut) by a consensus
of three experienced observers without knowledge of the
patient or treatment condition. For each patient, all three
stress images were interpreted separately in comparison with
same rest image. For visual analysis, the left ventricle was
divided into 17 segments using an apical, mid-, and basal
short-axis slice as well as a mid-vertical long-axis view. Each
segment was qualitatively scored using a 5-point scoring
system (0  normal, 1  mild, 2  moderate, 3  severe
reduction in photon activity, and 4  absence of photon
activity). For each image, a summed stress score (SSS) and
summed rest score (SRS) was calculated by adding the
scores for all 17 segments and within each vascular territory
(left anterior descending artery [LAD]  seven segments,
circumflex and right coronary artery [RCA]  five seg-
ments). Images and vascular territories with an SSS greater
than the respective SRS were classified as reversible. For
each image, a summed difference score (SDS) was calculated
by subtracting the SRS from the SSS. Images and vascular
territories with an SSS 4 and 2, respectively, were
considered normal.
Statistical analysis. Data are expressed as mean  one SD
or as proportions. Hemodynamic variables were analyzed
using repeated measures analysis of variance while the
Friedman statistic was used to analyze SPECT variables.
McNemars test for paired proportions was used to compare
overall and regional (per vessel) sensitivity. Chi-square or
the Fisher exact test was used to analyze clinical stress
Table 2. Hemodynamic Responses During Dipyridamole Stress Study With Placebo, Low-Dose
Metoprolol, and High-Dose Metoprolol
Placebo
Low-Dose
Metoprolol
High-Dose
Metoprolol
Pre-stress
HR (beats/min) 72  11 61  7* 59  7*
SBP (mm Hg) 142  15 136  12 135  20
DBP (mm Hg) 74  11 71  9 71  12
Rate-pressure product (HR  SBP) 10,260  2,150 8,410  1,350* 8,080  1,600*
Peak stress
HR (beats/min) 76  12§ 72  9 72  9
SBP (mm Hg) 135  15† 130  17 131  17
DBP (mm Hg) 70  9† 68  11 67  16
Rate-pressure product (HR  SBP) 10,470  2,350 9,440  1,960‡§ 9,480  1,950‡§
*p  0.001 vs. placebo; †p  0.05 vs. pre-stress ‡p  0.05 vs. placebo; §p  0.01 vs. pre-stress; p  0.001 vs. pre-stress.
Abbreviations as in Table 1.
Table 3. Clinical Effects of Low-Dose and High-Dose Metoprolol on Dipyridamole Stress
Testing End Points
Placebo Low-Dose Metoprolol High-Dose Metoprolol
Dipyridamole dose (mg) 48.1  8.8 48.1  8.8 48.1  8.8
Reason for termination
Completion of infusion 21 (100%) 21 (100%) 21 (100%)
Progressive angina 0 0 0
ST-T changes 0 0 0
Symptoms
Any symptom 11/21 (52.4%) 10/21 (47.6%) 10/21 (47.6%)
Chest discomfort 7/21 (33.3%) 5/21 (23.8%) 6/21 (28.6%)
Nausea 1/21 (4.8%) 1/21 (4.8%) 2/21 (9.5%)
Headache 2/21 (9.5%) 2/21 (9.5%) 3/21 (14.3%)
Flushing 1/21 (4.8%) 4/21 (19.0%) 2/21 (9.5%)
Dyspnea 1/21 (4.8%) 1/21 (4.8%) 1/21 (4.8%)
There were no significant differences between placebo, low-dose, and high dose metoprolol conditions.
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variables. Post-hoc comparisons were performed using ei-
ther a paired t test or the Wilcoxon signed-rank test.
Bonferroni adjustments were used as required. Significance
was set at p  0.05, and all analyses were two-tailed.
RESULTS
Patient population. Twenty-one patients (six female,
mean age of 64 years [range 50 to 82]) completed all four
MPI studies and constituted the study group. Four patients
had previous myocardial infarction. On coronary angiogra-
phy, five patients had single-vessel, eleven had double-
vessel, and five had triple-vessel disease. A stenosis 70%
was found in 14 LAD, 15 circumflex, and 13 RCAs.
Metoprolol titration. For each patient, the dosage of
metoprolol administered for the low-dose condition was
exactly 50% of that determined for the high-dose condition
(9.0  1.9 mg and 18.0  3.9 mg, respectively). Adminis-
tration of low- and high-dose metoprolol significantly
reduced heart rate, blood pressure, and double product
(Table 1).
Dipyridamole stress. In comparison with placebo, pre-
stress heart rate and double product were significantly lower
with low- and high-dose metoprolol (Table 2). Infusion of
dipyridamole resulted in an increase in heart rate and a
decrease in blood pressure with each condition. Despite a
more profound increase in heart rate with either dose of
metoprolol, double product at peak dipyridamole stress
remained significantly lower with each dose of metoprolol.
There were no differences in the incidence of symptoms
between each condition (Table 3).
Dipyridamole Tc-99m sestamibi imaging. Dipyridamole
myocardial perfusion imaging with placebo was normal in
three patients (14.3%), showed fixed defects in one (4.8%),
and reversible defects in 17 (80.9%). Results of DMPI with
low- and high-dose metoprolol were similar: normal in six
patients (28.6%), fixed defects in three (14.3%), and revers-
ible defects in 12 (57.1%). Sixteen patients (76.2%) had
similar DMPI results with placebo, low-dose, and high-
dose of metoprolol: normal in three patients (14.2%), fixed
defects in one (4.8%), and reversible defects in 12 (57.1%).
However, the SSS and SDS were significantly lower with
each dose of metoprolol (Fig. 1). In addition, the number of
segments with a score 1 or 2 on DMPI (reflecting the
size and severity of defects, respectively) as well as the
number of reversible segments were significantly lower with
metoprolol (Table 4).
The mean reduction in the SSS with low- and high-dose
metoprolol was 30.7% and 27.1%, respectively. Of the 18
patients with abnormal perfusion on DMPI with placebo,
11 (61.1%) had a greater than 25% reduction in the SSS
with either or both doses of metoprolol. Conversely, only
two patients (9.5%) had a greater than 25% increase in the
SSS with either dose of metoprolol. None of the patients
with normal perfusion on DMPI with placebo had abnor-
mal perfusion with metoprolol. Similar findings were ob-
served with the SDS (Fig. 2). There were five patients with
reversible defects with placebo, which was negated with
metoprolol (normal perfusion in three and fixed defects in
two). Three of these patients had multivessel disease. The
overall sensitivity of DMPI for detection of CAD was lower
with metoprolol than placebo (71.4% [15/21 patients] vs.
85.7% [18/21 patients], respectively), although this did not
achieve statistical significance (p  0.25). However, a
significantly lower sensitivity was found on a per vessel basis
(52.4% with low- and high-dose metoprolol [22/42 diseased
coronary vessels] vs. 69.1% with placebo [29/42 diseased
coronary vessels], p  0.039).
Images from three patients are illustrated (Figs. 3 to 5).
In Figure 3, DMPI with placebo demonstrated a large and
severe perfusion abnormality in the anterolateral, inferolat-
eral, and inferobasal regions. With metoprolol, the size and
severity of the perfusion abnormality on DMPI was reduced
by approximately 50% in visual assessment. This patient had
a 90% distal LAD stenosis, 70% proximal circumflex ste-
nosis, and an occluded first marginal. Figure 4 shows DMPI
images from a patient with an 85% RCA stenosis and a 90%
proximal LAD stenosis. With placebo, DMPI showed a
medium completely reversible anteroseptal, anteroapical, and
distal inferoapical perfusion abnormality. With each metopro-
lol dose, the anterior perfusion abnormality was reduced by
Figure 1. Impact of acute beta blocker therapy upon summed stress score
(SSS) and summed difference score (SDS) with dipyridamole Tc-99m
sestamibi single-photon emission computed tomography imaging. *p 
0.05; **p  0.01; ***p  0.001.
Table 4. Dipyridamole Tc-99m Sestamibi Imaging Results
Placebo
Low-Dose
Metoprolol
High-Dose
Metoprolol
Number of segments
scored 1 on DMPI
(defect extent)
6.4  3.7 4.6  3.5† 4.9  4.5*
Number of segments
scored 2 on DMPI
(defect severity)
3.5  3.4 2.4  2.9* 2.7  3.3
Number of reversible
segments on DMPI
5.6  4.1 3.3  3.7‡ 3.8  4.8*
*p  0.05 vs. placebo; †p  0.01 vs. placebo; ‡p  0.001 vs. placebo.
DMPI  dipyridamole myocardial perfusion imaging.
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Figure 2. Individual data points comparing the summed difference score (SDS) on dipyridamole Tc-99m sestamibi single-photon emission computed
tomography imaging after administration placebo and low-dose metoprolol and placebo and high-dose metoprolol. In both cases, the differences in the SDS
between placebo and each dose of metoprolol were statistically significant.
Figure 3. Multiple short-axis slices during dipyridamole Tc-99m sestamibi single-photon emission computed tomography (SPECT) imaging in a patient
with coronary artery disease after administration of placebo, low-dose metoprolol, and high-dose metoprolol, as well as Tc-99m sestamibi SPECT imaging
at rest. A large reversible anterolateral and inferolateral perfusion abnormality is shown with placebo, with at least 50% reduction in size and severity with
either dose of metoprolol.
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approximately 60% in visual assessment. Figure 5 shows
images from a patient with multivessel disease. As with the
other two cases, the extent and severity of perfusion abnor-
malities were reduced by at least 50% with both metoprolol
doses.
DISCUSSION
It is well recognized that several classes of cardiac drugs
reduce sensitivity as well as defect size and severity with
exercise MPI (4–8). It has been assumed that concomitant
cardiac drugs do not affect MPI results with vasodilator
stress, although recent data from Sharir et al. (15) suggests
a negative impact upon sensitivity as well as defect size and
severity. Our study was performed to evaluate the impact of
isolated beta-blocker therapy upon DMPI. Results demon-
strate a significant reduction in the size, severity, and
reversibility of defects after acute metoprolol administration.
These findings have important clinical implications in the
diagnostic and risk stratification assessment of patients
receiving beta-blocker therapy referred for vasodilator MPI.
Impact of antianginal drugs upon exercise MPI. Experi-
mental studies have shown that beta adrenergic blockade
reduces exercise-induced ischemia through alteration of
regional myocardial blood flow (16). In the clinical setting,
the sensitivity of exercise MPI is reduced in patients unable
to achieve a maximum predicted heart rate (1) or if receiving
antianginal drugs (5,8). Concurrent beta-blocker therapy
has also been shown to significantly reduce rate-pressure
product and the severity of defects with exercise MPI
(17–19). For these reasons, patients referred for exercise
MPI for the diagnosis of CAD are generally instructed to
discontinue antianginal drugs, particularly beta-blockers, for
at least 48 h before testing (18).
Impact of antianginal drugs upon vasodilator MPI. Data
regarding the impact of antianginal drugs upon detection of
CAD with vasodilator stress are contradictory. With echo-
cardiography, all three classes of antianginal drugs have been
shown to negatively impact detection of regional wall
motion abnormalities during dipyridamole stress (20). Sim-
ilarly, calcium channel blockers have been shown to nega-
Figure 4. Multiple short-axis slices during dipyridamole Tc-99m sestamibi single-photon emission computed tomography (SPECT) imaging in a patient
with coronary artery disease after administration of placebo, low-dose metoprolol, and high-dose metoprolol, as well as Tc-99m sestamibi SPECT imaging
at rest. A medium-sized anteroseptal, anteropical, and distal inferoapical perfusion abnormality is shown with placebo, with approximately 60% reduction
is size and severity noted with both doses of metoprolol.
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tively affect detection of CAD with DMPI (21). Con-
versely, two studies have suggested that antianginal drugs
have no impact on detection of CAD with vasodilator stress
and, if any, an increase in ischemia (22,23). Those studies
were retrospective in design and involved two separate
patient groups. Sharir et al. (15) compared data from the
same patients and found a significant reduction in sensitivity
and defect size, severity, and reversibility when DMPI was
performed without discontinuation of antianginal drugs. In
that study, the majority of patients were being treated with
calcium antagonists and/or nitrates, and 77% were receiving
multiple drugs at the time of testing. Our results suggest a
similar effect with DMPI in the presence of acute beta-
blocker therapy alone, even in low doses.
Potential mechanisms by which beta-blocker therapy
affects vasodilator MPI. Dipyridamole increases endoge-
nous adenosine concentrations by inhibiting adenosine
deaminase and preventing adenosine uptake into erythro-
cytes and vascular endothelial cells (24,25). Adenosine binds
to A2 receptors in the smaller coronary vessels, which are
coupled to stimulatory G-proteins. G-proteins increase
adenylate cyclase activity, which creates cAMP (26). In-
creasing cAMP within coronary arterioles causes vasodila-
tion by enhancing the rate of inactivation of myosin light
chain kinase, the enzyme responsible for triggering the
actin-myosin interaction that causes contraction (27). Va-
sodilation in a nonstenotic coronary vessel increases the
pressure gradient enhancing blood flow (28–32). Con-
versely, in a coronary vessel with significant stenosis, the
ability to dilate is compromised, and blood flow is shunted
away leading to a reduction in the driving pressure required
for collateral flow (33). This is the basis for the myocardial
steal phenomenon, whereby a greater percentage of blood
flow is shunted away from ischemic zones after dipyridam-
ole use (34,35).
Beta-2 receptors are coupled to the same types of stim-
ulatory G-proteins as the A2 receptors for adenosine (26). It
is possible that beta-2 receptor blockade within the coronary
vasculature attenuates the cAMP response from A2 receptor
stimulation. If this is the mechanism, it suggests that a
similar interaction may occur between adenosine and beta-
blockade. In addition, beta-blockers increase the time of
Figure 5. Multiple short-axis slices during dipyridamole Tc-99m sestamibi single-photon emission computed tomography (SPECT) imaging in a patient
with coronary artery disease after administration of placebo, low-dose metoprolol, and high-dose metoprolol, as well as Tc-99m sestamibi SPECT imaging
at rest. Multiple perfusion abnormalities are present with placebo with marked reduction in size and severity with both doses of metoprolol.
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diastole, which increases time for myocardial tissue perfu-
sion, potentially augmenting perfusion in ischemic zones
(25).
As described by Sharir et al. (15), calcium antagonists and
nitrates also exert a negative impact on accurate identifica-
tion of the presence and severity of CAD with MPI (15). In
this case, it may be a direct vasodilatory mechanism respon-
sible for attenuation of the myocardial steal phenomenon.
Study limitations. The number of patients evaluated was
limited. Although a trend towards a lower overall sensitivity
was noted, this did not reach statistical significance. How-
ever, a significant reduction in sensitivity on a per vessel
basis was found with each dose of metoprolol. This study
used an acute intravenous beta-blocker model rather than
chronic oral therapy. While it can be implied that the results
would be the same, this cannot be stated conclusively. In the
study of Sharir et al. (15), 31% of patients were receiving
chronic beta-blockers with similar results. These data sug-
gest that beta-blockers should be withheld in patients in
which the purpose of the study is diagnosis and/or risk
stratification of CAD. Such discontinuation of medications
should be performed with caution, however, as a rebound
effect in symptoms has been reported. If the purpose of the
study is to assess the effectiveness of medical therapy,
beta-blockers should be continued. This study examined the
effects of beta-blockade on DMPI, and not adenosine.
While the vasodilator effects are similar, adenosine may
have a greater hyperemic effect (36). Sundereswaran et al.
(37) evaluated two separate patient groups, one taking
antianginal drugs and the other not taking antianginal drugs
at the time of adenosine MPI, and found a lower sensitivity
in the former group. To our knowledge, there are no data on
the impact of acute beta-blockade on adenosine MPI.
Conclusions. In patients with CAD, acute administration
of intravenous beta-blocker significantly reduces the extent,
severity, and reversibility of defects with DMPI.
Acknowledgments
The authors express gratitude to the following individuals
who participated in this study: Dr. Maha Mikhail, Dr.
Carol Gemayel, Scott Harrison, CNMT, Andre Gagnon,
CNMT, Carole Benjamin, CNMT, Sylvie Lajeunesse,
CNMT, and Elizabeth Doucette for manuscript prepara-
tion.
Reprint requests and correspondence: Dr. Raymond Taillefer,
Nuclear Medicine, Centre Hospitalier de l’Universite´ de Montre´al
(pavillon Hotel-Dieu), Montre´al, Canada. E-mail: rtaillefer@
hotmail.com.
REFERENCES
1. Iskandrian AS, Heo J, Kong B, Lyons E. Effect of exercise level on the
ability of thallium-201 tomographic imaging in detecting coronary
artery disease: analysis of 461 patients. J Am Coll Cardiol 1989;14:
1477–86.
2. Heller GV, Ahmed I, Tilkemeier PL, Barbour MM, Garber CE.
Influence of exercise intensity on the presence, distribution, and size of
thallium-201 defects. Am Heart J 1992;123:909–16.
3. Heller GV, Ahmed I, Tilkemeier PL, Barbour MM, Garber CE.
Comparison of chest pain, electrocardiographic changes and thallium-
201 scintigraphy during varying exercise intensities in men with stable
angina pectoris. Am J Cardiol 1991;68:569–74.
4. Frisch C, DeSanctis R, Doge H, Reeves T, Weinberg S. Guidelines
for exercise testing: a report of the American College of Cardiology/
American Heart Association Task Force on Assessment of Cardio-
vascular Procedures (Subcommittee on Exercise Testing). J Am Coll
Cardiol 1986;8:725–38.
5. Hockings B, Saltissi S, Croft DN, Webb-Peploe MM. Effect of beta
adrenergic blockade on thallium-201 myocardial perfusion imaging. Br
Heart J 1983;49:83–9.
6. Martin GJ, Henkin RE, Scanlon PJ. Beta blockers and the sensitivity
of the thallium treadmill test. Chest 1987;92:486–7.
7. Burns RJ, Kruzyk GC, Armitage DL, Druck MN. Effect of anti-
anginal medications on the prognostic value of exercise thallium
scintigraphy. Can J Cardiol 1989;5:29–32.
8. Mahmarian JJ, Fenimore NL, Marks GF, et al. Transdermal nitro-
glycerin patch therapy reduces the extent of exercise-induced myocar-
dial ischemia: results of a double-blind, placebo-controlled trial using
quantitative thallium-201 tomography. J Am Coll Cardiol 1994;24:
25–32.
9. Shehata AR, Gillam L, Mascitelli V, et al. Impact of acute propranalol
administration on dobutamine induced myocardial ischemia as evalu-
ated by myocardial perfusion imaging and echocardiography. Am J
Cardiol 1997;80:268–72.
10. Smits P, Corstens FHM, Aengevaeren WRM, Wackers FJT, Thien
T. False-negative dipyridamole-thallium-201 myocardial imaging af-
ter caffeine infusion. J Nucl Med 1991;32:1538–41.
11. Heller GV, Dweik RB, Barbour MM, et al. Pretreatment with
theophylline does not affect adenosine-induced thallium-201 myocar-
dial imaging. Am Heart J 1993;126:1077–83.
12. Beller GA. Dipyridamole thallium-201 scintigraphy: an excellent
alternative to exercise scintigraphy. J Am Coll Cardiol 1989;14:
1642–4.
13. Bonaduce D, Muto P, Morgano G, et al. Effect of beta blockade on
thallium-201 dipyridamole myocardial scintigraphy. Acta Cardiol
1984;39:399–408.
14. Picano E. Dipyridamole echocardiography test/historical background
and physiologic basis. Eur Heart J 1989;10:365–76.
15. Sharir T, Rabinowitz B, Livschitz S, et al. Underestimation of extent
and severity of coronary artery disease by dipyridamole stress thallium-
201 single-photon emission computed tomographic myocardial perfu-
sion imaging in patients taking antianginal drugs. J Am Coll Cardiol
1998;31:1540–6.
16. Matsuzaki M, Patritti J, Tajimi T, Miller M, Kemper WS, Ross J.
Effects of -blockade on regional myocardial flow and function during
exercise. Am J Physiol 1984;247:H52–60.
17. Narahar K, Thompson C, Hazen J, Brizendine M, Mena I. The effect
of beta blockade on single photon emission computed tomographic
(SPECT) thallium-201 images in patients with coronary disease. Am
Heart J 1989;117:1030–5.
18. Hockings B, Saltissi S. Effect of beta adrenergic blockade on thallium-
201 myocardial perfusion imaging. Br Heart J 1983;49:83–9.
19. Muller-Suur R, Eiksson S, Strandber L. Comparison of adenosine and
exercise stress test for quantitative perfusion imaging in patients on
beta-blocker therapy. Cardiology 2001;95:112–8.
20. Lattanzi F, Picano E. Inhibition of dipyridamole-induced ischemia by
antianginal therapy in humans. Circulation 1991;83:1256–62.
21. Kubota I, Ikeda K, Igarashi H. Inhibition of dipyridamole-induced
myocardial ischemia by diltiazem in patients with coronary artery
disease. J Cardiovasc Pharmacol 1987;9:363–7.
22. Santoro G, Sciagra R, Buonamici P, Consoli N, Mazzoni V. Head-
to-head comparison of exercise stress testing, pharmacologic stress
echocardiography and perfusion tomography as first-line examination
for chest pain in patients without history of coronary artery disease.
J Nucl Cardiol 1998;1:19–27.
1482 Taillefer et al. JACC Vol. 42, No. 8, 2003
Acute Beta-Blockade and Dipyridamole Perfusion October 15, 2003:1475–83
23. Bridges A, Kennedy N, McNeill G. The effect of atenolol on
dipyridamole 201Tl myocardial perfusion tomography in patients with
coronary artery disease. Nucl Med Commun 1992;13:41–6.
24. Picano E. Dipyridamole echocardiography test: historical background
and physiologic basis. Eur Heart J 1989;10:365–72.
25. United States Pharmacopeial Convention. USPDI-Volume I, Drug
Information for the Health Professional. Englewood, CO: Microme-
dex, Inc., 2000.
26. Second messenger systems. In: Clark WG, Brater DC, Johnson AR,
editors. Goth’s Medical Pharmacology. St Louis, MO: Mosby Year
Book, 1992:13–7.
27. Katzung BG, Chatterjee K. Vasodilators and the treatment of angina
pectoris. In: Katzung BG, editor. Basic & Clinical Pharmacology.
New York, NY: McGraw-Hill, 2001:181–99.
28. Young DF, Tsai FY. Flow characteristics in models of arterial stenosis.
I. Steady flow. J Biomech 1973;6:395–410.
29. Young DF, Tsai FY. Flow characteristics in models of arterial stenosis:
II. Unsteady flow. J Biomech 1973;6:547–59.
30. Gould KL, Lipscomb K, Calvert C. Compensatory changes of the
distal coronary vascular bed during progressive coronary constriction.
Circulation 1975;51:1085–94.
31. Gould KL, Lipscomb K. Effects of coronary stenoses on coronary flow
reserve and resistance. Am J Cardiol 1974;34:48–55.
32. Flameng W, Wusten B, Schaper W. On the distribution of myocardial
flow. II. Effects of arterial stenosis and vasodilation. Basic Res Cardiol
1974;69:435–46.
33. Becker LC. Conditions of vasodilator-induced coronary steal in
experimental myocardial ischemia. Circulation 1978;57:1103–10.
34. Becker LC. Effect of nitroglycerin and dipyridamole on regional left
ventricular blood flow during coronary artery occlusion. J Clin Invest
1976;58:1287–96.
35. Nakamura M, Nakayaki O, Nose Y, Fukuyama T, Kikuchi Y. Effects
of nitroglycerin and dipyridamole on regional myocardial blood flow.
Basic Res Cardiol 1978;73:482–96.
36. Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD.
Effects of adenosine on human coronary arterial circulation. Circula-
tion 1990;82:1595–606.
37. Sundereswaran L, He ZX, Verani MS, Mahmarian JJ. Influence of
anti-anginal medications on the detection of coronary artery disease as
assessed by single photon emission computed tomography combined
with adenosine stress (abstr). Circulation 1996;94 Suppl I:I303.
1483JACC Vol. 42, No. 8, 2003 Taillefer et al.
October 15, 2003:1475–83 Acute Beta-Blockade and Dipyridamole Perfusion
